LSTA — Lisata Therapeutics, Inc.

Lisata Therapeutics Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Operating Expenses: $4.4 million for Q3 2025, down 17.3% from $5.3 million in Q3 2024.
  • R&D Expenses: $2 million, a 22.9% decrease from $2.5 million year-over-year.
  • G&A Expenses: $2.5 million, down 12.1% from $2.8 million in the prior year.
• Net Loss: $4.2 million for Q3 2025, improved from a loss of $4.9 million in Q3 2024.
• Cash Position: $19 million as of September 30, 2025, with a projected runway into Q1 2027.

2. Strategic Updates and Business Highlights:

• Certepetide Development: Positive preliminary results from ASCEND, iLSTA, and CENDIFOX trials, indicating potential effectiveness in various cancer treatments.
• Strategic Alliances:
  • Partnership with GATC Health to leverage AI in drug discovery.
  • Nonexclusive global license agreement with Catalent for certepetide in their SMARTag ADC technology.
• Regulatory Progress: Certepetide has received multiple special designations from the FDA and EMA, enhancing its development prospects.
• Patent Protection: A new composition of matter patent for certepetide has been issued, extending protection until March 2040.

3. Forward Guidance and Outlook:

• Anticipation of a "data and transaction-rich" period in the coming quarters, with several key milestones expected.
• Plans for a Phase III trial for certepetide are contingent upon securing additional funding, with ongoing discussions for potential partnerships to share costs.

4. Bad News, Challenges, or Points of Concern:

• Market Response: Despite positive clinical data, the company’s stock has not reacted favorably, attributed to broader negative market conditions affecting small-cap biotech firms.
• Funding Challenges: The current financing environment is difficult, making it challenging to raise necessary capital for the Phase III trial without significant dilution to shareholders.
• Clinical Trial Dependencies: Some trials are investigator-initiated, which may lead to unpredictable timelines and outcomes.

5. Notable Q&A Insights:

• Investor Sentiment: Management expressed frustration over the stock's lack of response to positive clinical results, attributing it to a confluence of negative market forces and a shareholder base that is more long-term focused.
• Future Licensing Strategy: The company is actively pursuing additional licensing opportunities, leveraging existing partnerships to attract new ones.
• Phase III Trial Funding: Discussions are ongoing to find partners who can contribute to the funding of the Phase III trial for ASCEND, with a focus on minimizing shareholder dilution.

Overall, Lisata Therapeutics is making significant strides in its clinical development and strategic partnerships, but faces challenges in market perception and funding that could impact its future growth.